Cubist Pharmaceuticals Given Consensus Rating of “Buy” by Brokerages (NASDAQ:CBST)
Shares of Cubist Pharmaceuticals (NASDAQ:CBST) have earned a consensus rating of “Buy” from the seventeen analysts that are presently covering the company, AnalystRatingsNetwork reports. Six research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $75.21.
Cubist Pharmaceuticals (NASDAQ:CBST) traded up 4.29% on Friday, hitting $71.49. 325,667 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a 52 week low of $48.23 and a 52 week high of $82.12. The stock’s 50-day moving average is $68.1 and its 200-day moving average is $70.42. The company’s market cap is $5.384 billion.
Cubist Pharmaceuticals (NASDAQ:CBST) last announced its earnings results on Tuesday, April 22nd. The company reported $0.30 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.33 by $0.03. The company had revenue of $261.20 million for the quarter, compared to the consensus estimate of $285.24 million. During the same quarter in the prior year, the company posted $0.34 earnings per share. The company’s quarterly revenue was up 13.6% on a year-over-year basis. On average, analysts predict that Cubist Pharmaceuticals will post $0.58 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on CBST shares. Analysts at Gabelli initiated coverage on shares of Cubist Pharmaceuticals in a research note on Friday. They set a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note on Thursday. They now have a $72.00 price target on the stock. Finally, analysts at Ned Davis Research upgraded shares of Cubist Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.